ALLMedicine™ Hypertriglyceridemia Center
Research & Reviews 2,269 results
https://doi.org/10.1158/1078-0432.CCR-22-2939
Clinical Cancer Research : an Official Journal of the Ame... Wang T, Sun X et. al.
Feb 4th, 2023 - To investigate the efficacy and safety of the novel orally active phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor in relapsed and/or refractory follicular lymphoma (FL) patients who had received at least two prior systemic treatments. Histol...
https://doi.org/10.1007/s11886-022-01831-0
Current Cardiology Reports; Bhat S, Sarkar S et. al.
Feb 3rd, 2023 - Omega-3 fatty acids (n-3 FA) lower triglycerides, have anti-inflammatory properties, and improve metabolism. Clinical evidence of cardiovascular benefit with omega-3 fatty acids is mixed. We discuss mechanisms providing biological plausibility of ...
https://doi.org/10.1097/YIC.0000000000000448
International Clinical Psychopharmacology; De Carlo V, Grancini B et. al.
Feb 3rd, 2023 - The present cross-sectional, retrospective study aimed to assess the prevalence of cardiovascular disease (CVD) risk factors and metabolic syndrome in a sample of psychiatric patients treated with long-acting injectable antipsychotics (LAIs). The ...
https://doi.org/10.1097/MJT.0000000000001566
American Journal of Therapeutics; Wang YH, Liu CY et. al.
Feb 3rd, 2023 - Lurasidone Successfully Reversed Clozapine-Induced Type 2 Diabetes Mellitus and Hypertriglyceridemia in a Patient With Schizophrenia.|2023|Wang YH,Liu CY,Her YN,Wu HH,Yao CY,|
https://doi.org/10.1097/MED.0000000000000802
Current Opinion in Endocrinology, Diabetes, and Obesity; Hussain A, Al Rifai M et. al.
Feb 2nd, 2023 - In this review, we will summarize some of the landmark clinical trials of triglyceride-lowering therapies and review updates in clinical guidelines with regards to treatment of elevated triglyceride levels. Accumulating evidence from epidemiologic...
Guidelines 4 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019936
Orphanet Journal of Rare Diseases; Mosbah H, Donadille B et. al.
Apr 21st, 2022 - Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to pathogenic variants of the LMNA gene. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole N...
https://doi.org/10.1016/j.jacc.2021.06.011
Journal of the American College of Cardiology; Virani SS, Morris PB et. al.
Aug 2nd, 2021 - 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.|2021|Virani SS,Morris PB,Agarwa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985771
Current Oncology (Toronto, Ont.); Blais N, Adam JP et. al.
Jan 4th, 2021 - The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive metastatic non-small cell lung cancer, is associated with dyslipidemia in over 80% of patients. Clinical trial protocols for the management of l...
https://doi.org/10.1016/j.maturitas.2020.03.007
Maturitas Anagnostis P, Bitzer J et. al.
Mar 27th, 2020 - Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein choles...
Drugs 909 results see all →
Clinicaltrials.gov 275 results
https://clinicaltrials.gov/ct2/show/NCT05610280
Jan 27th, 2023 - This is a Phase 3, multi-center, placebo-controlled study of up to 1312 participants with hypertriglyceridemia and atherosclerotic cardiovascular disease. The study consists of 3 periods: 1) Screening Period: Week -8 to Week -1 (up to 8 weeks); 2)...
https://clinicaltrials.gov/ct2/show/NCT05552326
Jan 26th, 2023 - This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study in up to approximately 390 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation...
https://clinicaltrials.gov/ct2/show/NCT02262832
Jan 25th, 2023 - Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with the very rare condition of generalized lipodystrophy have...
https://clinicaltrials.gov/ct2/show/NCT02262806
Jan 25th, 2023 - Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with lipodystrophy have leptin deficiency secondary to lack of...
https://clinicaltrials.gov/ct2/show/NCT05079919
Jan 25th, 2023 - This is a multi-center, randomized, double-blind, placebo-controlled study in up to approximately 540 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation in the s...
News 276 results
https://www.medpagetoday.com/infectiousdisease/covid19/102487
Jan 3rd, 2023 - An oral remdesivir analogue (VV116) was just as good as nirmatrelvir-ritonavir (Paxlovid) for the treatment of mild-to-moderate COVID-19 in adults at risk for severe disease, and may be safer, results of a phase III trial from China suggested. Sus...
https://www.mdedge.com/rheumatology/article/260163/gout/metabolic-syndrome-may-promote-gout-young-men
Heidi Splete
Dec 15th, 2022 - Metabolic syndrome is associated with a significantly increased risk for gout in young men, but the risk can be mitigated by improvement in individual components of the syndrome, based on data from a pair of population-based studies totaling more.
https://www.mdedge.com/cardiology/article/259219/lipid-disorders/triglyceride-lowering-fails-show-cv-benefit-large-fibrate
Ted Bosworth
Nov 5th, 2022 - CHICAGO – Despite a 25% reduction in triglycerides (TGs) along with similar reductions in very-low-density lipoprotein (VLDL), and remnant cholesterol, a novel agent failed to provide any protection in a multinational trial against a composite end.
https://www.medscape.com/viewarticle/983610
Nov 5th, 2022 - Despite a 25% reduction in triglycerides (TGs) along with similar reductions in very-low-density lipoprotein (VLDL), and remnant cholesterol, a novel agent failed to provide any protection in a multinational trial against a composite endpoint of m...
https://www.onclive.com/view/pyrotinib-plus-trastuzumab-docetaxel-prolongs-pfs-in-her2-metastatic-breast-cancer
Oct 14th, 2022 - The addition of pyrotinib to trastuzumab (Herceptin) and docetaxel significantly improved progression-free survival (PFS) vs trastuzumab/docetaxel alone in patients with HER2-positive metastatic breast cancer, according to data from the phase 3 PH...